68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Cancer Patients
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is
able to provide superior sensitivity and specificity to detect primary prostate tumor and its
metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was prospectively
designed to evaluate the diagnostic value of 68Ga-P16-093, a novel radiopharmaceutical
targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of prostate cancer
patients.